NCT03623646View on ClinicalTrials.gov

Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

February 26, 2022

Study Completion Date

February 14, 2023

Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Chemoradiotherapy arm

Radiation Therapy in combination with Chemotherapy (Cisplatin)

DRUG

Immunotherapy + Radiotherapy arm

Radiation Therapy in combination with Immunotherapy drug (Durvalumab)

Trial Locations (2)

31059

Institut Universitaire du Cancer Toulouse (IUCT-O), Toulouse

Unknown

CHU Bordeaux, Bordeaux

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Claudius Regaud

OTHER